国家: 加拿大
语言: 法文
来源: Health Canada
FLURALANER; Moxidectine
INTERVET CANADA CORP
250MG; 12.5MG
Solution
FLURALANER 250MG; Moxidectine 12.5MG
Topique
15G/50G
Prescription
Chats
Numéro de groupe d'ingrédients actifs (GIA) :0261730001
APPROUVÉ
2019-08-23
VITRECTO Fluralaner and Moxidectin Topical Solution PACKAGE INSERT Version 05MAY2023 1 Confidential DIN 02491729, 02491737, 02491745 Pr ViTRECTO ® Fluralaner and Moxidectin Topical Solution Veterinary Use Only DESCRIPTION: VITRECTO (Fluralaner and Moxidectin Topical Solution) contains 280 mg/mL (28% w/v) of fluralaner and 14 mg/mL (1.4% w/v) of moxidectin. Each single use tube is formulated to provide a minimum dose of 40 mg/kg body weight of fluralaner and 2 mg/kg of moxidectin. Non-Medicinal Ingredients: Butylhydroxytoluene, Dimethylacetamide (DMA), Glycofurol, Diethyltoluamide (DEET), Acetone. THERAPEUTIC CLASSIFICATION: Antiparasitic INDICATIONS : VITRECTO is indicated for cats and kittens 6 months of age and older and weighing 1.2 kg or greater. VITRECTO is indicated every 2 months for: - The treatment and prevention of flea infestations ( _Ctenocephalides felis_ ) - The treatment and control of tick infestations with _Ixodes scapularis _ (black-legged tick) - The prevention of heartworm disease caused by _Dirofilaria immitis_ VITRECTO is effective for the treatment and control of tick infestations with _Haemaphysalis _ _longicornis_ (Asian longhorned tick) for 12 weeks. VITRECTO is also indicated for the treatment of infections with intestinal roundworm ( _Toxocara _ _cati_ ; 4 th stage larvae, immature adults and adults) and hookworm ( _Ancylostoma tubaeforme_ ; 4 th stage larvae, immature adults and adults). DOSAGE AND ADMINISTRATION : VITRECTO should be administered topically as a single dose every 2 months according to the DOSAGE SCHEDULE below to provide a minimum dose of 40 mg fluralaner and 2 mg moxidectin per kg body weight. It is important to exactly follow a bi-monthly administration to ensure optimum prevention of heartworm disease in cats. For prevention of heartworm disease, VITRECTO administration should begin one month after the first expected exposure to mosquitoes and continue at 2-month intervals until last exposure to mosquitoes. VITRECTO Fluralaner and Moxidectin Topical Solution PACKAG 阅读完整的文件